Key facts
- PhotoPharmics’s last known valuation is $51.8M (Nov 2025).
- It has raised $50.9M across 8 recorded rounds; the latest was Early Stage VC ($26.2M) in Oct 2023.
- Notable investors include MedTech Innovator, National Institutes of Health, Kickstart (US), Frazier Group, Angel Star Ventures — 13 tracked in total.
- PhotoPharmics has filed 9 Form Ds with the SEC since 2012, most recently Apr 2025 ($23.9M sold to 27 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 8 rounds
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for PhotoPharmics
Funding rounds
8 roundsAbout PhotoPharmics
Developer of non-invasive therapies designed to improve the lives of patients suffering from neurological disorders and addictions. The company's therapies offer chrono-biological treatments for Parkinson's disease, and a medical edge-lit device used to treat neurological disorders, enabling medical institutions to restore the health of patients suffering from Parkinson's disease.
- Sector
- Healthcare
- HQ
- Lehi, UT, United States
- Founded
- 2011
- Employees
- 9
- Website
- photopharmics.com/
- Ownership
- Privately Held (backing)
PhotoPharmics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PhotoPharmics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PhotoPharmics in its N-PORT filings yet. We sweep new filings monthly.